Shortage of repackaged bevacizumab for ophthalmic use

On October 11, 2024, Pine Pharmaceuticals, the largest producer of repackaged bevacizumab (Avastin^®), communicated that it would no longer be a supplier of repackaged, prefilled bevacizumab syringes.

Our preferred products include Avastin, Byooviz, Cimerli, Eylea, Eylea HD, Lucentis, and Vabysmo. To avoid access issues or treatment delays for members receiving this treatment, we encourage providers to reach out if necessary to our prior authorization department for an alternative antivascular endothelial growth factor drug for our members. All expedited requests for a Part B drug will have a determination made and the enrollee will be notified of the decision as expeditiously as the enrollee’s health condition requires, but no later than 24 hours after the request is received.